Table 1.
Patient characteristics by treatment groupa.
| Characteristic | All patients (N = 97) | Treatment | P value | |
|---|---|---|---|---|
| Abiraterone acetate (n = 48) | Docetaxel (n = 49) | |||
| Prior treatment | 0.03b | |||
| None | 59 (61) | 23 (48) | 36 (73) | |
| Surgery | 28 (29) | 19 (40) | 9 (18) | |
| RT | 10 (10) | 6 (13) | 4 (8) | |
| Mets at diagnosis | 64 (66) | 27 (56) | 37 (76) | 0.045b |
| TSG alterations | ||||
| TP53 |
35 (36) (n = 96) |
17 (35) |
18 (38) (n = 48) |
0.83b |
| PTEN | 30 (31) | 17 (35) | 13 (27) | 0.34b |
| BRCA | 16 (16) | 11 (23) | 5 (10) | 0.09b |
| APC | 10 (10) | 3 (6) | 7 (14) | 0.19b |
| AR | 11 (11) | 9 (19) | 2 (4) | 0.02b |
| RB1 | 6 (6) | 3 (6) | 3 (6) | 0.98b |
| Total TSG alterations | (n = 96) | (n = 48) | 0.93b | |
| None | 45 (47) | 21 (44) | 24 (50) | |
| 1 | 33 (34) | 18 (38) | 15 (31) | |
| 2 | 16 (17) | 8 (17) | 8 (17) | |
| 3 | 2 (2) | 1 (2) | 1 (2) | |
| MDB | 0.009b | |||
| Low | 34 (35) | 23 (48) | 11 (22) | |
| High | 63 (65) | 25 (52) | 38 (78) | |
| Visceral progression | 29 (30) | 15 (31) | 14 (29) | 0.77b |
| Bone progression |
61 (64) (n = 96) |
29 (62) (n = 47) |
32 (65) | 0.71b |
| Laboratory values | ||||
| Alkaline phosphatase, IU/L |
103.0 (13.0–1380.0) (n = 96) |
99.0 (66.0–260.0) |
108.5 (13.0–1380.0) (n = 48) |
0.050c |
| LDH, U/L |
191.0 (130.0–407.0) (n = 80) |
194.0 (131.0–247.0) (n = 47) |
186.0 (130.0–407.0) (n = 33) |
0.81c |
| Hemoglobin, g/dL |
12.5 (7.4–16.1) (n = 95) |
12.2 (9.0–15.0) (n = 48) |
13.0 (7.4–16.1) (n = 47) |
0.52c |
LDH lactate dehydrogenase, MDB metastatic disease burden, Mets metastases, RT radiotherapy, TSG tumor suppressor gene.
aValues are No. of patients (%) or median (range).
bPearson χ2 test.
cKruskal–Wallis rank sum test.